Entering text into the input field will update the search result below

Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

May 21, 2023 9:01 AM ETargenx SE (ARGX) Stock, BPMC Stock, SRPT StockBy: Joshua Fineman, SA News Editor2 Comments
Book about Myasthenia gravis and medication, injection, syringe and pills

Marcelo Ricardo Daros/iStock via Getty Images

Argenx (NASDAQ:ARGX) Blueprint Medicines (NASDAQ:BPMC) and Sarepta Therapeutics (NASDAQ:SRPT) are likely takeover targets in the biotech sector, according to a Wedbush analyst.

Year-to-date there have been over $70 billion announced acquisitions in the biotech space and for the entire year last

Recommended For You

Related Stocks

SymbolLast Price% Chg
SRPT
--
BPMC
--
ARGX
--